Welcome to our dedicated page for Janux Therapeutics SEC filings (Ticker: JANX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Janux Therapeutics filings document a clinical-stage biopharmaceutical issuer developing tumor-activated immunotherapies through the TRACTr, TRACIr and ARM platforms. Recent 8-K reports furnish financial results and business updates covering clinical programs such as JANX007, JANX014, JANX011 and JANX008, as well as cash-position commentary and pipeline prioritization.
The company’s regulatory record also includes a material definitive agreement for the Bristol Myers Squibb collaboration, with license, development, commercialization, milestone and royalty terms. Proxy and governance filings document director elections, board-classification matters, executive compensation, pay-versus-performance disclosure and officer or director changes.
Janux Therapeutics, Inc. President and CEO David Alan Campbell exercised stock options to acquire 7,000 shares of common stock at an exercise price of $4.21 per share. Following the transaction on July 8, 2026, he holds 388,582 common shares directly and 697,550 stock options remaining, with the exercised option series immediately exercisable and expiring on March 9, 2031.
Janux Therapeutics, Inc. reported that its Chief Medical Officer, William Go, M.D., Ph.D., departed the company on June 23, 2026. The departure was treated as a termination without “Cause” under Janux’s Change in Control and Severance Benefit Plan.
The company has begun searching for a new Chief Medical Officer. Until a successor is appointed, existing clinical leaders will collectively handle the responsibilities. Janux stated that this transition does not change its development strategy, regulatory plans, or previously disclosed clinical timelines, and that Dr. Go’s departure did not stem from any disagreement over operations, policies, or practices.
Janux Therapeutics, Inc. reported insider-related equity awards linked to RA Capital–associated entities. An arrangement for Dr. Jake Simson includes a grant of 5,500 restricted stock units (RSUs), each representing one share of common stock, and 15,500 stock options with a $13.66 exercise price. The RSUs vest on the earlier of June 11, 2027 or the next annual stockholder meeting, subject to Dr. Simson’s continuous service, while the options vest in equal monthly installments over the 12 months following June 11, 2026 and in any case by the next annual meeting. Dr. Simson holds these awards for the benefit of RA Capital funds, must deliver any net shares or cash to the adviser to offset advisory fees, and the reporting persons disclaim beneficial ownership except for any pecuniary interest.
Janux Therapeutics director Jake Simson reported equity awards tied to his board service. He received 5,500 restricted stock units, each representing one share of common stock, vesting on the earlier of June 11, 2027 or the next annual stockholder meeting, subject to continuous service. He was also granted options for 15,500 shares at an exercise price of $13.66 per share, vesting in equal monthly installments over the 12 months following June 11, 2026 and fully vested by the next annual meeting, subject to continued service. After these awards, his reported direct common stock holdings total 11,750 shares. Under an arrangement with RA Capital Management, these RSUs and options are held for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund II, L.P., and Simson is obligated to turn over any net stock or cash received, so he disclaims beneficial ownership.
Janux Therapeutics director Winston Kung received new equity awards. He was granted 5,500 restricted stock units, each representing one share of common stock, and 15,500 stock options with an exercise price of $13.66 per share.
The RSUs vest on the earlier of June 11, 2027 or the next annual stockholder meeting, subject to continuous service. The options vest in equal monthly installments over the 12 months following June 11, 2026, and will in any case be fully vested by the next annual meeting, also subject to continued service. After the grant, Kung directly holds 11,750 shares of common stock.
Janux Therapeutics, Inc. director Natasha Hernday received new equity compensation awards. She was granted 5,500 restricted stock units (RSUs), each representing one share of common stock. These RSUs vest on the earlier of June 11, 2027 or the next annual stockholder meeting, subject to her continuous service.
She was also granted a stock option for 15,500 shares of common stock at an exercise price of $13.66 per share, vesting in equal monthly installments over the 12 months following June 11, 2026 and fully vesting no later than the next annual stockholder meeting, contingent on continued service. Following these grants, she directly holds 15,481 shares of common stock.
Janux Therapeutics director Eric Dobmeier received new equity awards. He was granted 5,500 restricted stock units, each representing one share of common stock, which will vest on the earlier of June 11, 2027 or the next annual stockholder meeting, subject to continued service.
He was also granted options to buy 15,500 shares of common stock at an exercise price of $13.66 per share, expiring on June 10, 2036. These options vest in equal monthly installments over the 12 months following June 11, 2026 and will in any case be fully vested by the next annual stockholder meeting, subject to continued service. Following these grants, he directly holds 15,481 common shares.
Janux Therapeutics director Vickie L. Capps received new equity awards. She was granted 5,500 restricted stock units, each convertible into one share of common stock, increasing her direct holdings to 79,598 shares. She also received options on 15,500 shares at an exercise price of $13.66 per share, vesting over 12 months and fully by the next annual stockholder meeting, subject to continued service.
Janux Therapeutics director Ronald W. Barrett received new equity awards. He was granted 5,500 restricted stock units, each representing one share of common stock, increasing his direct common stock holdings to 11,750 shares. He also received a stock option for 15,500 shares at an exercise price of $13.66 per share, expiring on June 10, 2036.
The RSUs vest on the earlier of June 11, 2027 or the next annual stockholder meeting, subject to his continuous service. The option vests in equal monthly installments over the 12 months following June 11, 2026, and will in any case be fully vested by the next annual stockholder meeting, also contingent on continued service.
Janux Therapeutics, Inc. reported results of its 2026 Annual Meeting of Stockholders held on June 11, 2026. As of the April 17, 2026 record date, 60,961,546 shares of common stock were outstanding, and 53,744,922 shares were present or represented by proxy.
Stockholders elected Class II directors Natasha Hernday and Eric Dobmeier to serve until the 2029 annual meeting. They also ratified Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026, and approved, on an advisory basis, the compensation of named executive officers.